In this podcast, we interviewed Ricardo Baptista, Lead Process Development Scientist, Cell and Gene Therapy Catapult, UK, about his impressions on current bioprocessing technologies for stem cell therapy manufacturing and possible future innovations.
In this podcast, we interviewed Dr. Robert Preti about the past, present, and future of global cell therapy manufacturing. We also discussed major industry milestones, manufacturing challenges, and opportunities for the further improvements.
Robert A. Preti, PhD
Chief Executive Officer and President, Hitachi Chemical Advanced Therapeutics Solutions, LLC
General Manager, Regenerative Medicine Business Sector, Hitachi Chemical Co. Ltd.
Dr. Robert “Bob” Preti is the co-founder and the visionary behind the successful growth and development strategy of PCT (on October 2, 2017 renamed Hitachi Chemical Advanced Therapeutics Solutions, LLC or “HCATS”) over much of the last two decades. Upon PCT’s acquisition by Hitachi Chemical Co., Ltd. in May 2017, Bob’s role expanded to General Manager, Regenerative Medicine Business Sector of Hitachi Chemical, responsible for development, management and oversight of the global business operations of Hitachi Chemical’s regenerative medicine business unit. Bob built HCATS to meet a recognized need for high quality manufacturing and development services in an emerging industry. Bob is currently Chairman for the Alliance for Regenerative Medicine, where, among other activities, he previously served as Vice Chairman and in other roles. Bob holds a BS degree in biology from Fordham University, and a MS degree and Doctorate, both in biology, from New York University.
017 - Cell Harvesting – Selecting a technology compatible with cell density and feed turbidity on Cell Culture Dish.
In this podcast and accompanying article, we interviewed Silke Bergheim-Pietza, Global Product Manager Depth Filtration, Pall. We discussed challenges faced in the cell harvesting step, in particular, selecting the best cell harvesting method based on the cell density and feed turbidity of the process and meeting the demand of increasing cell densities. Download the cell harvesting technology selection guide and use the guide to compare the latest single-use harvesting technologies.
In this podcast, we interviewed Jonathan Royce, Business Leader, Chromatography Resins, GE Healthcare Life Sciences, about the biggest challenges in Downstream biomanufacturing including overcoming bottlenecks, changing antibody structures and bioburden control. Jonathan shared how a purification platform can address some of these issues and discusses purification challenges that still need to be resolved.
In this podcast, we interviewed Dr. Paul Wotton, CEO, about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapies that do not trigger fibrosis
In this podcast, we interviewed Jonathan Royce, Business Leader, Chromatography Resins, GE Healthcare Life Sciences, about the evolution of Protein A including the latest developments in Protein A chromatography resins. We also discussed what the future holds for this purification mainstay and how it can continue to address the changing needs of biopharma.
In this podcast, we interviewed Joakim Lundvist, Modality Manager, BioProcess™ Hardware, GE Healthcare about large-scale buffer management challenges. Buffer preparation is known to be one of the most resource-intensive activities in biomanufacturing as large volumes of buffers and process liquids are often required.
We examined the biggest challenges in buffer management and explored how technologies like inline conditioning can provide possible solutions.
In this podcast, we interviewed Alyssa Master, Ph.D., Senior Manager of Science and Applications, Nucleus Biologics about some of the challenges of working with FBS, why not all FBS is created equal and suggestions for FBS customers who are trying to navigate these issues.
We began the interview by discussing what FBS is and how it differs from other types of serum. Alyssa explained that FBS is a bi-product of the meat and dairy industry and it is great for in vitro cell growth because it contains a cocktail of growth factors. FBS is biochemically different from other sera like adult bovine serum or even newborn calf serum. Due to these biochemical differences, FBS has become the gold standard and as a result it is more expensive.
Alyssa continued that because of its ability to support cells in vitro it is widely used throughout academia, biotech, large pharma and bioproduction, particularly in cell therapy and vaccine biomanufacturing. I asked why so many use FBS and Alyssa said that it works well for most lines and is readily available. Because it is animal derived, it already contains cytokines and growth factors in the right combination to support cell growth.
View all show notes at:
011 - Do you have to sacrifice antibody titer for quality? Employing cell biology to get the best of both worlds
In this podcast, we interviewed Dr. Adam Elhofy, Ph.D., Chief Scientific Officer, Bio-Ess, about the relationship between antibody titer and product quality attributes such as glycosylation. Dr. Elhofy shares his thoughts on both challenges and opportunities for optimizing both high titer and glycosylation profiles.